Method for prophylaxis of post-operative adhesion

FIELD: medicine, surgery.

SUBSTANCE: method involves administration of verapamil solution in the amount 20-30 mg by intraperitoneal route by spraying method on visceral and parietal peritoneum on the final stage of operation. Invention promotes to reducing frequency in formation and relapse of post-operative adhesions. Invention can be used for prophylaxis of post-operative adhesions.

EFFECT: improved method for prophylaxis.

2 ex

 

The invention relates to medicine and can be used in surgical practice.

Known way to prevent the SETTLEMENT of blockers of calcium ions, including the introduction of a 0.25% solution of verapamil in the amount of 5-10 ml intravenously as enzymatic protect tissue from damage during hypoxia (Vigoleno, Lavaclan, Oaabi Postoperative adhesions. M.: Medicine, 1998, pages 178-179) [1].

The disadvantage of this method is expressed manifestation of arterial hypotension, atrioventricular block.

There is a method of treatment of keloid and hypertrophic scars by direct injection verapamil in the rumen (Jacek Puchala Department of Pediatric Surgery Polish Surgery in chilhood VOL.lV-V-3 july 1996)[2].

The disadvantages of the method are: extreme pain, uneven exposure and risk of resorptive effects.

The invention aims: reducing the frequency of formation and recurrence of post-operative adhesions.

The problem is solved in that the solution verapamil 0.25% in the quantity of 20-30 mg administered intraperitoneally administered by the sputtering technique on the visceral and parietal peritoneum at the final stage of the operation.

Used dose is subtherapeutic, the introduction of verapamil in fewer ineffective, and in quantities greater than the upper limit may cause hemodynamic changes.

The proposed method was treated 23 patients (mean age of 27.7 years; the average time of occurrence of pregnancy is 2 years 6 months). Studies made on the basis of the MUSES GB No. 8 Omsk during 2001-2002, the Clinical results were evaluated visually for early control of laparoscopy on the 3rd day of the postoperative period and on the dynamics of cellular and biochemical composition of peritoneal fluid. The follow - up period of 6 months. The result of applying the described method of treating PIC is the absence of pathological subjective symptoms: aching pain in the lower abdomen and lower back, dyspareunia, algomenorea and the onset of the desired pregnancy (n=3).

Example 1

Patient R., aged 29, arrived in 3 gynecology Department of the MUSES GB No. 8 25.11.01, complaining of the absence of pregnancy within 3 years; painful, heavy menstruation.

26.11.01.- operative laparoscopy, hydrotubation, adhesio-lysis, conservative myomectomy. The severity of adhesions-II scale (ball system of an estimation of severity of adhesions on Mynbaeva O.A., 1997). At the final stage of the operation adhesiolysis introduced 20 mg 0,25% R-RA verapamil. Hemodynamic parameters (heart rate, BP) in the early postoperative period were within normal limits.

28.11.01 control laparoscopy: spaek the abdominal cavity and small pelvis no, hemorrhagic effusion 15 ml; fallopian tube freely passable for contrast.

Upon further observation is fully normalized menstrual function, desired pregnancy occurred after 8 months.

Example 2

Patient S., 25 years old, was admitted to the hospital MUSES GB No. 8 5.12.01, complaining of the absence of pregnancy within 6 years, dyspareunia. From previous surgeries: 1988-appendectomy with drainage of the abdominal cavity; illness - subacute bilateral adnexitis in 1999 Character of menstrual function is not broken.

6.12.01.- operative laparoscopy, lysis of adhesions, salpingostomy with 2 sides. The severity of adhesions - III (minbaeva). At the final stage of the operation entered 20 mg 0,25% R-RA verapamil.

10.12.01. control laparoscopy, hydrotubation: tubes are permeable, recurrence of adhesions there. In the following, outpatient continued absorbable therapy, hormonal contraception for 3 months. At the control examination in may 2002. complaints the patient is not present, the recommended “spontaneous” pregnancy.

The proposed method of profilaktiki PIC allows you to restore the reproductive potential of women, to prevent the need for repeated surgical intervention to reduce the severity of subjective and objective patologica what some of the symptoms.

The proposed method is cheap, easy to perform, well tolerated.

The way to prevent postoperative adhesions (PIC), including the introduction of a 0.25%aqueous solution of verapamil, characterized in that the solution verapamil in quantity of 20-30 mg administered intraperitoneally administered by the sputtering technique on the visceral and parietal peritoneum at the final stage of the operation.



 

Same patents:

FIELD: medicine, obstetrics.

SUBSTANCE: at the first stage of pregravidic training one should introduce leukinferon per 10000 IU intramuscularly every other day 10 times, at the second stage it is necessary to perform 3 seances of discrete plasmapheresis. The present innovation enables to decrease the frequency in developing gestosis and the risk for abortion due to normalized activity of female immune system, that in its turn, enables to stop virusemia and virusuria, prevent fetoplacental failure and intrauterine fetal infectioning.

EFFECT: higher efficiency of training.

3 ex, 1 tbl

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new derivatives of glucopyranosyloxybenzylbenzene represented by the formula (I): wherein R1 represents hydrogen atom or hydroxy(lower)alkyl; R2 represents lower alkyl group, lower alkoxy-group and lower alkylthio-group being each group is substituted optionally with hydroxy- or (lower)alkoxy-group, or to its pharmaceutically acceptable salts. Also, invention relates to pharmaceutical composition eliciting hypoglycemic activity and to a method for treatment and prophylaxis of hyperglycemia-associated diseases, such as diabetes mellitus, obesity and others, and to their intermediate compounds. Invention provides preparing new derivatives of glucopyranosyloxybenzylbenzene that elicit the excellent inhibitory activity with respect to human SGLT2.

EFFECT: valuable medicinal properties of compounds.

13 cl, 2 tbl, 2 ex

FIELD: chemical and pharmaceutical industry, in particular method for production of healthful and therapeutic composition based on plant raw materials.

SUBSTANCE: claimed method includes separate preparation of fine dispersed powder of at least one plant with crushing degree of 10-200 mum; separate extraction of at least one plant with aqueous ethanol in ratio raw material/extractant from 1:5 to 1:20, respectively; separate preparation and optionally concentration of at least one plant juice followed by blending of obtained powder, extract and juice in ratio of (1-20):(9-90):(9-90), respectively.

EFFECT: new healthful and therapeutic composition with increased content of vitamins, proteins, carbohydrates, flavonoids, etc. and improved action on organism.

4 cl,4 ex, 1 tbl

FIELD: veterinary science.

SUBSTANCE: one should apply a honey-tissue preparation that contain emulsion out of the walls of pregnant uterus and ovaries without cow's yellow bodies 6.0 ml, natural bee honey 5.0 g, isotonic sodium chloride solution 2.0 ml sodium benzoate caffeine 1.5 g to be introduced into dorsal lumbar muscles both from the right and from the left per a half of the dosage being equal to 0.03-0.04 ml/kg either once or twice at 6-7-d-long interval. The present innovation enables to improve metabolism, normalize the work of hormonal and nervous systems, normalize functions of uterine muscles at hypo- and atonias, at delayed afterbirth and restore affected ovarian functions.

EFFECT: higher efficiency of therapy.

FIELD: medicine, anesthesiology, traumatology, orthopedics, thoracic surgery.

SUBSTANCE: about 1.5-2 min before spreading the affected lung it is necessary to deepen anesthesia due to injecting phenthanyl at the dosage of 10-12 mcg/kg body weight. The present innovation provides safety of operations of ventral spondyledesis out of transthoracic and thoracodiaphragmatic accesses, stability of arterial pressure level and patient's heart rate, decreases stress loading upon a patient that, in its turn, favors the prophylaxis of intraoperative complications.

EFFECT: higher efficiency of anesthesiological protection.

2 cl, 1 ex

FIELD: medicine, obstetrics, gynecology, mammology.

SUBSTANCE: method involves administration of alcohol-air mixture into cyst cavity wherein the amount of air and alcohol is similar and represents 40-60% of the content volume evacuated from the cyst cavity. Invention promotes to prophylaxis of diseases relapses and prevention of iatrogenic complications associated with carrying out this procedure. Invention can be used for treatment of patients with cystic mactopathy.

EFFECT: improved method for treatment.

2 tbl

FIELD: veterinary science.

SUBSTANCE: animals should be introduced with antihistamine serum (AHS) subcutaneously at the dosage of 4.0-5.0 ml in combination with myxoferon at the quantity of 60-75 dosages and vitamin C at the dosage of 1.0-1.5 ml/animal, once daily, thrice at interval of 5-7 d. Application of AHS in combination with myxoferon and ascorbic acid provides active stimulation of immunological reactivity, increases total body resistance I animals and causes no toxic effects and allergic reactions.

EFFECT: higher efficiency of correction.

3 tbl

FIELD: ecology, medicine, toxicology, experimental biology.

SUBSTANCE: the present innovation deals with studying the mechanisms to withdraw heavy metals, cadmium, in particular, out of the body in animals and preventing intoxication due to introducing zeolite irlite-1 as 6%-suspension through the probe into animal's stomach at the quantity of 2.5% against body weight simultaneously with daily introduction of cadmium sulfate solution either subcutaneously or through the probe into animal's stomach at the dosage of 0.5 mg/kg.

EFFECT: higher efficiency of prophylaxis.

2 ex, 4 tbl

FIELD: ecology, medicine, toxicology, experimental biology.

SUBSTANCE: the innovation deals with introducing zeolite irlite-1 as 6%-suspension at the quantity of 2.5% against body weight. The method provides withdrawing cobalt out of the body in experimental animals in case of acute intoxication.

EFFECT: higher prophylaxis of intoxication.

2 dwg, 1 ex, 2 tbl

FIELD: medicine, anesthesiology, surgery.

SUBSTANCE: in preoperational and early postoperational periods after planned and urgent operations one should intramuscularly inject adrenogangliolytics: benzohexonium 0.18 - 0.22 mg/kg, droperidol 0.078 - 0.083 mg/kg and obzidan 0.016 - 0.022 mg/kg thrice daily; moreover, the time for their introduction after operation depends upon the type of anesthetic preparation applied to carry out spinal anesthesia, that is: if one applied lidocaine as local anesthetic the above-mentioned adrenogangliolytics should be introduced 2 h after the end of operation, and if marcaine was applied as local anesthetic - 3 h after the end of operation. The innovation enables to prevent disorders of central and peripheral hemodynamics at carrying out spinal anesthesia in perioperational period.

EFFECT: higher efficiency.

FIELD: organic synthesis.

SUBSTANCE: invention provides compounds of general formula I:

, where R1 represents -CO-Ra, -SO2-Rb, or aryl optionally substituted by lower alkoxy, wherein Ra represents cycloalkyl, cycloalkyl(lower)alkyl, cycloalkyloxy, aryl, aryloxy, aryl(lower)alkyl, aryl(lower)alkoxy, aryloxy(lower)alkyl, aryl-S-(lower)alkyl, aryl(lower)alkenyl, provided that aryl group can be optionally substituted by halogen, lower alkyl, hydroxy, nitro, cyano, lower alkoxy, phenyl, CF3, cyano(lower)alkyl, lower alkyl-C(O)NH, lower alkyl-CO, and lower alkyl-S; heteroaryl, heteroaryl(lower)alkyl, or heteroaryl(lower)alkoxy, provided that heteroaryl group is 5- or 6-membered ring or bicyclic aromatic group constituted by two 5- or 6-membered rings including 1-3 heteroatoms selected from oxygen, nitrogen, and sulfur and that heteroaryl group can be optionally substituted by lower alkoxy; Rb represents aryl, aryl(lower)alkyl, or heteroaryl, aryl group optionally substituted by halogen, cyano, or lower alkyl-C(O)NH; R2 and R3 represent hydrogen atoms; R4 representshydrogen or lower alkyl; R5 represents hydrogen, lower alkyl, cycloalkyl, benzodioxyl, or aryl optionally substituted by lower alkyl, halogen, lower alkoxy, hydroxy, or (lower)alkyl-C(O)O; n is 1 or 2; and pharmaceutically acceptable salts thereof and/or pharmaceutically acceptable esters thereof. Invention also provides a pharmaceutical composition exhibiting inhibitory activity with regard to cysteine proteases of the cathepsin family, which composition comprises compound of formula I, pharmaceutically acceptable recipient, and/or adjuvant.

EFFECT: increased choice of cysteine protease inhibitors.

34 cl, 1 tbl, 13 ex

The invention relates to medicine, in particular to pulmonology and concerns of conservative stopping pulmonary hemorrhage

The invention relates to medicine, more specifically to anesthesiology and critical care medicine, and can be used for controlled lowering of blood pressure during surgical procedures under General anesthesia

FIELD: organic synthesis.

SUBSTANCE: invention provides compounds of general formula I:

, where R1 represents -CO-Ra, -SO2-Rb, or aryl optionally substituted by lower alkoxy, wherein Ra represents cycloalkyl, cycloalkyl(lower)alkyl, cycloalkyloxy, aryl, aryloxy, aryl(lower)alkyl, aryl(lower)alkoxy, aryloxy(lower)alkyl, aryl-S-(lower)alkyl, aryl(lower)alkenyl, provided that aryl group can be optionally substituted by halogen, lower alkyl, hydroxy, nitro, cyano, lower alkoxy, phenyl, CF3, cyano(lower)alkyl, lower alkyl-C(O)NH, lower alkyl-CO, and lower alkyl-S; heteroaryl, heteroaryl(lower)alkyl, or heteroaryl(lower)alkoxy, provided that heteroaryl group is 5- or 6-membered ring or bicyclic aromatic group constituted by two 5- or 6-membered rings including 1-3 heteroatoms selected from oxygen, nitrogen, and sulfur and that heteroaryl group can be optionally substituted by lower alkoxy; Rb represents aryl, aryl(lower)alkyl, or heteroaryl, aryl group optionally substituted by halogen, cyano, or lower alkyl-C(O)NH; R2 and R3 represent hydrogen atoms; R4 representshydrogen or lower alkyl; R5 represents hydrogen, lower alkyl, cycloalkyl, benzodioxyl, or aryl optionally substituted by lower alkyl, halogen, lower alkoxy, hydroxy, or (lower)alkyl-C(O)O; n is 1 or 2; and pharmaceutically acceptable salts thereof and/or pharmaceutically acceptable esters thereof. Invention also provides a pharmaceutical composition exhibiting inhibitory activity with regard to cysteine proteases of the cathepsin family, which composition comprises compound of formula I, pharmaceutically acceptable recipient, and/or adjuvant.

EFFECT: increased choice of cysteine protease inhibitors.

34 cl, 1 tbl, 13 ex

FIELD: medicine, surgery.

SUBSTANCE: method involves administration of verapamil solution in the amount 20-30 mg by intraperitoneal route by spraying method on visceral and parietal peritoneum on the final stage of operation. Invention promotes to reducing frequency in formation and relapse of post-operative adhesions. Invention can be used for prophylaxis of post-operative adhesions.

EFFECT: improved method for prophylaxis.

2 ex

FIELD: organic chemistry, nematocides.

SUBSTANCE: invention relates to compounds of the formula (I): wherein Ar1 and Ar2 mean independently of one another unsubstituted phenyl or mono- or multi-substituted phenyl with substitutes having independent of one another values and chosen from the group including halogen atom, (C1-C6)-alkyl or halo-(C1-C6)-alkyl; Q1 means -OCH2 or -C(O); Q2 means a direct bond or -C(O); R3 means hydrogen atom; R4, R5 and R6 mean independently of one another hydrogen atom or (C1-C6)-alkyl; W means O or S atom; a means 1, 2, 3 or 4; b means 0; n means 0 or 1. Also, method proposes a method for synthesis of compound of the formula (I) and carriers and/or dispersers also. Also, invention proposes using compound of the formula (I) for control of nematodes. Invention provides preparing derivatives of benzamidoacetonitrile used in control of nematodes.

EFFECT: improved preparing method, valuable properties of compounds.

10 cl, 2 tbl, 19 ex

Organic compounds // 2286775

FIELD: veterinary, organic chemistry.

SUBSTANCE: invention relates to application of aminoacetonitrile compounds of general formula I to control nematode-endoparasite of warm-blooded livestock and warm-blooded domestic animals; to produce pharmaceutical composition for said purpose. Method for controlling of nematode-endoparasite of warm-blooded livestock and warm-blooded domestic animals by using composition of present invention; pharmaceutical composition also are disclosed. Said compounds represent known pesticides for plant protection. Discovered is activity thereof against species Trichostrongylus and Haemunchus parasitizing in gastro-intestinal tract.

EFFECT: veterinary preparations of prolonged action.

35 cl, 6 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: method involves intravenously dropping 5 mg of Ginipral dissolved in 100 ml of 0.9% sodium chloride solution. 5 mg of Verapamyl dissolved in 100 ml of 0.9% sodium chloride solution is intravenously dropped second frequency corresponding to wavelength of 292 nm; photons of the third frequency corresponding to wavelength from 700 to 1400 nm. Photons of the first frequency are produced with one or more continuous radiation laser. Photons of the second and third frequency are produced with one or more pulsating radiation laser. The first, second and third frequency photons are applied to atomic vapor containing several Thallium isotopes. Photons of the first frequency pump Thallium isotope assembly in base state and transfer them to metastable state with energy level of 7793 cm-1 over the first excited state distinguished by energy level of 26477.6 cm-1 relative to zero level of the basic state. The second state photons excite Thallium atoms set in metastable state to intermediate state being the second exited state having energy of 42040.0 cm-1 or 42049.9 cm-1 relative to zero energy of the basic state. Photons of the third frequency ionize the set of atoms belonging to intermediate state. Mentioned isotopic ions are accumulated by applying electric field to the vapor.

EFFECT: enhanced effectiveness in separating thallium isotopes.

10 CL, 7 dwg

FIELD: medicine.

SUBSTANCE: method involves intravenously introducing 7.5 mg of Verapamyl dissolved in 100 ml of 0.9% sodium chloride solution as infusion therapy at 2 ml/min rate.

EFFECT: enhanced effectiveness of treatment.

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to novel ester compounds represented by the formula (1): wherein values for R1, R2, A, X, R3, R4, Alk1, Alk2, l, m, D, R8 and R9 are determined in the invention claim. Also, invention relates to inhibitor of matrix metalloproteinase (MTP), a pharmaceutical composition able to inhibit activity of MTP selectively, agents used in treatment or prophylaxis of hyperlipidemia, arteriosclerosis, coronary artery diseases, obesity, diabetes mellitus or hypertension wherein the pharmaceutical composition is prepared in capsulated formulation, and to a biphenyl compound of the formula (100) given in the invention description.

EFFECT: valuable medicinal properties of compounds.

53 cl, 78 tbl, 17 ex

FIELD: organic chemistry, derivatives of amino acids, medicine, pharmacy.

SUBSTANCE: invention relates to novel derivatives of phenylalanine that inhibit cellular adhesion mediated by α4 integrin that are considered to be useful in treatment and prophylaxis of inflammatory diseases. Invention relates to compounds of the formula (I): or its pharmaceutically acceptable salt, or ester wherein R1 means bromine atom; R2 means halogen atom, (C1-C6)-alkyl or (C1-C6)-alkoxy-group. Also, invention relates to a method for synthesis of compound of the formula (I), a pharmaceutical composition, using compound of the formula (I), in manufacturing a medicinal agent and to intermediate compounds of formulae (II) , (III) or (IV) .

EFFECT: valuable medicinal properties of derivatives and pharmaceutical composition.

17 cl, 10 ex

Up!